Abstract
WITH TIGHTER DEADLINES FOR the launch of new trials, new technology to increase transparency and streamline data management, and plans to consolidate the number of groups in its Clinical Trials Cooperative Group Program, the National Cancer Institute (NCI) has moved swiftly to implement some of the changes recommended by the Institute of Medicine (IOM) in April 2010. But questions remain about whether recommended funding increases and other changes will occur.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
